echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Novavax new crown trimeric protein vaccine is comparable to mRNA vaccine, clover biology is on the way

    Novavax new crown trimeric protein vaccine is comparable to mRNA vaccine, clover biology is on the way

    • Last Update: 2021-06-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 14, 2021, Novavax announced that the new crown vaccine NVX-CoV2373 Phase III clinical success, with an overall protection rate of 90.
    4% and a critical illness protection rate of 100%
    .

    NVX-CoV2373 is a trimeric full-length S protein vaccine, using Matrix-M adjuvant
    .

    Clover Biology’s SCB-2019 is also a trimeric S protein vaccine, constructed on the basis of its Trimer-Tag technology, and is currently in the phase III clinical stage
    .

    In the first phase of clinical trials, Clover Biology used GlaxoSmithKline’s AS03 adjuvant and Dynavax’s CpG1018 plus aluminum adjuvant, respectively.
    Due to the stronger side effects of AS03 adjuvant, Clover used CpG1018 plus aluminum adjuvant in the third phase of clinical trials
    .

    AS03 adjuvant and CpG1018 are two of the six adjuvants used in all marketed vaccines.
    The mechanism of action is shown in the figure below
    .

           

           to sum up

           In the new crown epidemic, the mRNA vaccine has been crushed with an overwhelming protection rate advantage.
    Novavax's trimeric protein vaccine is the first protein vaccine with a protection rate comparable to that of the mRNA vaccine
    .


    The SCB-2019, which has a similar design, is expected to release mid-term results in the middle of the year, and the results are expected


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.